Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maarten van Eijk"'
Autor:
Maarten van Eijk, Marit A. C. Vermunt, Erik van Werkhoven, Erica A. Wilthagen, Alwin D. R. Huitema, Jos H. Beijnen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Administration of single-agent docetaxel in a weekly schedule may offer similar efficacy, with a more favorable toxicity profile, compared to a three-weekly schedule in patients with metastatic breast cancer. Methods The original
Externí odkaz:
https://doaj.org/article/945d1a6f4e4f43f1ab4abdce43983aae
Publikováno v:
Anti-Cancer Drugs. 34:281-289
Autor:
Maarten van Eijk, Huixin Yu, Emilia Sawicki, Vincent A. de Weger, Bastiaan Nuijen, Thomas P. C. Dorlo, Jos H. Beijnen, Alwin D. R. Huitema
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:71-82
Purpose Orally administered paclitaxel offers increased patient convenience while providing a method to prolong exposure without long continuous, or repeated, intravenous infusions. The oral bioavailability of paclitaxel is improved through co-admini
Autor:
Dick Pluim, Alwin D. R. Huitema, Thomas P. C. Dorlo, Maarten van Eijk, Jos H. Beijnen, Serena Marchetti
Publikováno v:
The Pharmacogenomics Journal. 21:336-345
The anticancer drug docetaxel exhibits large interpatient pharmacokinetic and pharmacodynamic variability. In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the
Autor:
Marianne Keessen, Debbie Robbrecht, Rob Kessels, Marit A C Vermunt, Bas Thijssen, Niven Mehra, Ferry A.L.M. Eskens, Andries M. Bergman, Lot A. Devriese, Julie M Janssen, Maarten van Eijk, Jos H. Beijnen
Publikováno v:
Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)
Cancer Reports, 4(4):e1367. Wiley-Blackwell Publishing Ltd
Cancer Reports
Cancer Reports, 4(4):e1367. Wiley-Blackwell Publishing Ltd
Cancer Reports
BACKGROUND: ModraDoc006 is an oral formulation of docetaxel, which is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in
Autor:
Maarten, van Eijk, Dick, Pluim, Thomas P C, Dorlo, Serena, Marchetti, Alwin D R, Huitema, Jos H, Beijnen
Publikováno v:
The pharmacogenomics journal. 21(3)
The anticancer drug docetaxel exhibits large interpatient pharmacokinetic and pharmacodynamic variability. In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 84(3), 487. Springer Verlag
Cancer Chemotherapy and Pharmacology, 84(3), 487. Springer Verlag
Enzymes of the cytochrome P450 (CYP) subfamily 3A and 2C play a major role in the metabolism of taxane anticancer agents. While their function in hepatic metabolism of taxanes is well established, expression of these enzymes in solid tumors may play
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d576161468475bfc5b84de8ce3dfa662
https://dspace.library.uu.nl/handle/1874/394287
https://dspace.library.uu.nl/handle/1874/394287